Effects of hyperbaric oxygen on vascular endothelial function in patients with slow coronary flow by Li, Yuan et al.
Address for correspondence: Dr. Tao Wang, Department of Cardiology, the Third Hospital of Hebei Medical University, 
China, tel: +86-13582102651, e-mail: docwt781130@163.com
Received: 30.06.2017 Accepted: 22.10.2017
BASIC SCIENCE AND EXPERIMENTAL CARDIOLOGY
Cardiology Journal 
2018, Vol. 25, No. 1, 106–112
DOI: 10.5603/CJ.a2017.0132 
Copyright © 2018 Via Medica
ISSN 1897–5593
106 www.cardiologyjournal.org
ORIGINAL ARTICLE
Effects of hyperbaric oxygen on vascular endothelial 
function in patients with slow coronary flow
Yuan Li1, Huiping Zhang2, Yi Liang3, Wei Wang3, Tongshun Xu1,  
Jifang Zhang1, Wenliang Xiao4, Tao Wang4
1Department of Cardiology, The Fourth Hospital of Shijiazhuang, China 
2Department of Otolaryngology, Heibei People’s Hospital, China 
3Department of Hyperbaric Oxygen Therapy, the Third Hospital of Hebei Medical University, China 
4Department of Cardiology, the Third Hospital of Hebei Medical University, China
Abstract
Background: To improve therapy for slow coronary flow (SCF), the effects of hyperbaric oxygen (HBO) 
therapy on vascular endothelial function in SCF patients is the focus of this investigation. 
Methods: Ninety-eight patients who exhibited chest discomfort were retrospectively analyzed, and di-
agnosed with SCF by coronary artery angiography at the Third Hospital of Hebei Medical University, 
Shijiazhuang, China from 2014 to 2016. The patients were divided into two groups according to the 
following treatment: HBO group (n = 48) and the control group (n = 50). Patients in the control group 
were administrated with conventional treatment, while those in the HBO group were administrated 
HBO therapy for 4 weeks in addition to conventional treatment. To evaluate the effects of HBO on vas-
cular endothelial functions, plasma levels of nitric oxide (NO), calcitonin gene-related peptide (CGRP), 
endothelin-1 (ET-1), high sensitivity C-reactive protein (hsCRP) as well as endothelial-dependent flow-
mediated vasodilation (FMD) of the brachial artery were measured in both groups before and after their 
respective treatments.
Results: There were no significant differences in plasma levels of NO, ET-1, CGRP, hsCRP nor in 
FMD measurements between the two groups before treatment (p > 0.05). Moreover, the levels of all the 
parameters measured showed no significant changes before and after treatment in the control group. 
However, when comparing the control group, FMD and plasma NO and CGRP levels were significantly 
increased in the HBO group after treatment (p < 0.01), whereas hsCRP and ET-1 levels decreased 
dramatically (p < 0.001). 
Conclusions: The HBO treatment in addition to conventional therapy may significantly improve the 
vascular endothelial function in SCF patients. (Cardiol J 2018; 25, 1: 106–112)
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Introduction
Slow coronary flow (SCF) is the phenomenon 
characterized by the slow passage of contrast in 
the absence of obstructive coronary artery dis-
eases, including coronary artery coronary spasm, 
thrombosis, coronary artery dilatation, heart valve 
disease and connective tissue disease [1]. Patients 
with SCF often exhibit angina pectoris or acute 
coronary syndrome, have high rates of re-hospi-
talization and are more likely to be diagnosed with 
other cardiovascular-related diseases [2, 3].
Hyperbaric oxygen (HBO) therapy is defined 
as subjecting patients to oxygen breathing at ambi-
ent temperatures which are greater than normal 
atmospheric pressure. It has been demonstrated 
that increasing oxygen partial pressure and blood 
oxygen levels, enhances tissue oxygen dispersion, 
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and increases blood flow in the ischemic area as 
well as improves myocardial aerobic metabolism 
and energy metabolism [4]. It can also decrease 
the heart rate, and reduce myocardial contractil-
ity so that myocardial oxygen consumption will be 
decreased and relieve the symptoms of hypoxia 
myocardium [4].
In this study, HBO therapy was applied on SCF 
patients in addition to the conventional treatments. 
Before and after HBO treatment, under investiga-
tion were the effects of HBO on SCF patients by 
examining endothelial-dependent flow-mediated 
vasodilation (FMD) of the brachial artery, and the 
plasma levels of nitric oxide (NO), endothelin-1 
(ET-1), calcitonin gene-related peptide (CGRP), 
and high sensitivity C-reactive protein (hsCRP). 
These results demonstrated that HBO treatment 
can significantly improve the vascular endothelial 
functions, which might explain how HBO therapy 
improves the symptoms of cardiovascular diseases.
Methods
Objects
Ninety-eight patients who exhibited chest 
pain or chest discomfort were retrospectively 
analyzed, and diagnosed with SCF by coronary 
artery angiography in the Third Hospital of Hebei 
Medical University from 2014 to 2016. This study 
was approved by the ethics committee of the third 
hospital in Hebei Medical University. Informed 
consent was signed by all patients who participated 
in this study.
Diagnosis of SCF
Judkins technique and corrected Thromboly-
sis in Myocardial Infarction (TIMI) frame count 
(CTFC) were used for the diagnosis of SCF. All 
the patients were evaluated by two independent 
experienced physicians (deputy chief physician), 
and average values were taken into account. Pa-
tients with CTFC values greater than normal range 
(15 ≤ CTFC ≤ 27) were diagnosed with SCF [5].
Treatment
Before the surgery of coronary angiography, all 
patients were administered conventional medica-
tions with the same dosage for anti-platelet, anti-
coagulation, vessel expansion, and lipid regulation 
according to the guide for treatment for coronary 
heart disease and angina (Table 1). 
For the HBO group, patients who had stable 
hemodynamics with no arrhythmia nor angina 
pectoris, were administrated HBO therapy with 
an initial pressure of 0.2 MPa (2ATA) for 20 min in 
a cabin. Next, patients were given pure oxygen 
2 × 40 min, with a 5–10 min break with cabin air 
(0.2 MPa) in between. After treatment, the pres-
sure of the cabin was decompressed in 20 min. The 
whole procedure lasted about 120 min per treat-
ment. Patients from the HBO group were treated 
using this procedure once per day and 6 times per 
week for 4 weeks. The patients in the control group 
were not treated with HBO therapy.
During the HBO treatment, patient’s heart 
rate, blood pressure changes, and other symptoms 
of discomfort were closely monitored. In addition, 
several concerns should be taken into consid-
eration for HBO treatment: 1) the pressure in 
the treatment should not be higher than 0.2 MPa; 
2) and the process of compression and decom-
pression should be slow and smooth; 3) the pres-
sure regulator should be stable; 4) before HBO 
treatment, patients should be administrated with 
vascular smooth muscle dilatation drugs, such as 
isosorbide mononitrate.
FMD measurement 
Before measurement, patients stopped taking 
any drugs which might affect the measurement. 
Patients avoided drinking caffeine-containing bev-
erages and food, and had fasted for more than 4 h.
For the measurement, the brachial artery 
2–15 cm above the elbow was used as the target 
artery. The distance between the brachial artery 
and intima of the brachial artery was measured 
on the longitudinal section. The mean value was 
calculated by 3 measurements at the same site. 
The base diameter of patient brachial artery under 
relaxed status (D1) was determined first. Then the 
reactive hyperemia was measured at the distal end 
of the target artery. The sphygmomanometer was 
inflated to 300 mm Hg pressure, and decompressed 
to 0 mm Hg within 4 min. The reactive hyperemia 
(D2) was measured 60–90 s after decompression. 
The recovered brachial artery diameter (D3) was 
measured after a 15 min break, while the bra-
chial artery diameter (D4) was measured 4–5 min 
after administration with 0.5 mg of sublingual 
nitroglycerin. To calculate the FMD and endothe-
lium-independent diastolic function by measuring 
nitrate-mediated dilatation (NMD), the following 
formulas were applied: 
 — FMD = (D2 – D1)/D1 × 100%
 — NMD = (D3 – D4)/D4 × 100%
All operations were performed blindly by two 
experienced, high-grade B-ultrasonographers, and 
the mean values were calculated.
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Measurement of NO, ET-1, CGRP and 
hsCRP
The plasma levels of ET-1 and hsCRP were 
measured by enzyme-linked immunosorbent as-
say (ELISA; ET-1 kit: Shanghai Yuanye Biological 
Technology Co., Ltd; HsCRP assay: Shanghai 
Hengyuan Biological Technology Co., Ltd). NO 
levels were measured using a nitric acid reductase 
assay (Nanjing completed the Institute of Bioengi-
neering). The expression of CGRP was measured 
by radioimmunoassay (Institute of East Asian 
Immunology, PLA General Hospital). All experi-
ments were performed according to manufacturer’s 
instructions.
Statistical analysis
To perform statistical analysis, SPSS16.0 was 
applied. The data is presented as mean ± standard 
deviation (×– ± S). For comparison of the same 
group, student paired t-test was used, while for 
comparisons between the two groups the grouped 
t-test was applied. c2 analysis was applied and 
statistical significance was set at p value < 0.05. 
Results
Comparison of general clinical conditions 
between the two groups of patients
Ninety-eight SCF patients were divided into 
two groups: the HBO group (22 females and 
26 males, age: 42–69; 57.96 ± 10.26), and the con-
trol group (23 females and 27 males, age: 42–71; 
56.26 ± 9.52). No significant difference was found in 
sex, age, body mass index, family history of coronary 
heart disease, fasting blood glucose levels, blood 
pressure and heart rate between the two groups 
(Table 2). No significant difference was found in 
CTFC between the HBO group (39.5 ± 8.2; n = 48) 
and control group (37.3 ± 9.6; n = 50) (Table 2). 
None of the patients were diagnosed with coronary 
artery dissection, coronary aneurysm, hyperten-
sion 2 and above, myocardial infarction, coronary 
thrombosis, cardiac insufficiency, liver and kidney 
dysfunction nor had they had any signs of infection. 
Furthermore, none of the patients were diagnosed 
with pneumothorax, severe emphysema, open 
empty tuberculosis with hemoptysis history, retinal 
detachment, uncontrolled visceral bleeding, Eus-
tachian tube obstruction or any other hyperbaric 
oxygen contraindications. 
FMD and NMD measurements
Since SCF patients have been reported to 
suffer from endothelial dysfunction [6, 7], to eval-
uate the effects of HBO on SCF patients are 
endothelium-dependent or independent, FMD 
and NMD levels of patients were measured be-
fore and after HBO treatment. No remarkable 
difference in FMD was observed between HBO 
and control groups before treatment (Fig. 1A). 
Moreover, no significant difference was found in 
FMD before and after treatment in the control 
group (Fig. 1A). However, interestingly, after HBO 
therapy, patients from the HBO group showed 
significantly higher level of FMD compared to 
patients from the control group after treatment 
Table 1. Comparison of general clinical conditions between the two groups of patients.
Medication Dosage Effect Mechanisms Company
Aspirin 100 mg/day Inhibition of platelet 
aggregation
Block the formation  
of thromboxane A2  
in platelets
Bayer Healthcare Co. Ltd., 
Germany
Ticagrelor 180 mg/day Inhibition of platelet 
aggregation
An antagonist against 
P2Y12 receptor
AstraZeneca  
Pharmaceutical Co. Ltd., UK
Metoprolol  
tartrate
50 mg/day Reduce heart rate; 
relieve the chest pain 
due to poor blood flow
b1 receptor blocker AstraZeneca  
Pharmaceutical Co. Ltd., UK
Isosorbide  
mononitrate
40 mg/day Dilate the blood  
vessels to reduce  
the blood pressure; 
reduce the occurrence 
of angina
Nitrate-class drug to  
release nitric oxide, 
which increases  
cGMP level 
Lunan Beite  
Pharmaceutical Co. Ltd., 
China
Atorvastatin 20 mg/day Hypolipidemic;  
improve the vascular  
endothelial function
Inhibit HMG-CoA  
reductase, which plays 
essential roles in  
production of cholesterol
Pfizer Pharmaceuticals Ltd., 
USA
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(10.86 ± 4.26 vs. 8.39 ± 3.81; p < 0.01; Fig. 1A). 
To specify the effects of HBO treatment on en-
dothelium-dependent function, NMD was also 
measured, which increases the coronary flow in an 
endothelium-independent manner. No significant 
difference in NMD was found before and after 
treatment between groups, indicating that HBO 
treatment improves vascular endothelial functions 
(Fig. 1B).
Plasma NO, ET-1, CGRP and hsCRP  
measurements
To further investigate the potential mecha-
nisms of HBO treatment on vascular endothe-
lial functions, plasma levels of NO [8], ET-1 [8], 
CGRP [9] were analyzed, these were considered 
as biomarkers for vascular endothelial functions, 
and hsCRP, a maker of the inflammatory response 
[10, 11]. There were no significant differences 
in plasma levels of NO, ET-1, CGRP and hsCRP 
between the groups before treatment. After treat-
ment, compared to control patients, the patients 
who undertook HBO therapy exhibited signifi-
cantly higher plasma levels of NO (32.28 ± 9.24 vs. 
26.50 ± 8.95 µM; p < 0.01; Fig. 2A) and CGRP 
(30.78 ± 8.23 vs. 25.96 ± 6.28 pg/mL; p < 0.01; 
Fig. 2B), and significant reductions of ET-1 (14.46 ± 
± 6.04 vs. 19.57 ± 6.51 pg/mL; p < 0.001; Fig. 2C) 
Table 2. Comparison of baseline clinical conditions between two groups of patients.
Patients HBO Control P
Sex (male/female) 26/22 27/23 0.987
Ages 57.96 ± 10.26 56.26 ± 9.52 0.4978
Body mass index [kg/m2] 27.80 ± 2.99 28.39 ± 3.78 0.3948
Family history of CAD (yes/no) 16/32 19/31 0.630
Fasting blood glucose [mmol/L] 5.67 ± 0.73 5.49 ± 0.69 0.2126
Blood level of TC [mmol/L] 4.59 ± 0.77 4.80 ± 0.61 0.1370
Blood level of LDL-C [mmol/L] 2.91 ± 0.68 3.02 ± 0.65 0.4150
Blood level of HDL-C [mmol/L] 1.88 ± 0.46 1.91 ± 0.35 0.7165
Heart rate [bpm] 67 ± 10 71 ± 11 0.0630
Hypertension 17 (35.42%) 19 (38.00%) 0.791
History of smoking 15 (31.25%) 17 (34.00%) 0.772
Corrected TIMI frame count 39.5 ± 8.2 37.3 ± 9.6 0.2219
HBO — hyperbaric oxygen; CAD — coronary heart disease; TC — total cholesterol; LDL-C — low-density lipoprotein cholesterol;  
HDL-C — high-density lipoprotein cholesterol; TIMI — Thrombolysis in Myocardial Infarction
Figure 1. Flow-mediated vasodilation (A) and nitrate-mediated dilatation (B) measurements between control and 
hyperbaric oxygen (HBO) groups; *p < 0.01.
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and hsCRP (3.93 ± 1.56 vs. 5.21 ± 1.79 mg/L; 
p < 0.001; Fig. 2D) levels. No significant differ-
ences in plasma levels of NO, ET-1, CGRP and 
hsCRP were observed before and after treatment 
in the control group (Fig. 2A–D). These results 
further confirmed the effects of HBO treatment 
on vascular endothelial functions.
Discussion
Slow coronary flow affects 1–7% of patients 
who are tested by angiography due to clinical 
suspicion of cardiovascular diseases [12]. The 
pathological mechanisms underlying SCF are still 
unclear. Accumulating evidence suggests that mi-
crovascular lesions or functional abnormities are 
associated with the onset of SCF [13]. Pekdemir et 
al. [8] reported an imbalanced released of ET-1 and 
NO in SCF patients. In particular, ET-1 levels were 
exceptionally high in SCF patients. These results 
imply that SCF patients may suffer from impair-
ment of endothelial function. Indeed, in another 
independent study, Signori et al. [6] claimed that 
SCF patients suffered from endothelial dysfunc-
tion in both arteries and veins, and implied that 
SCF could be a global vascular phenomenon. Fur-
thermore, they found that the level of C-reactive 
protein, an independent risk factor for SCF, is 
significantly higher in SCF patients. In addition, 
Yoon et al. [7] observed lower FMD values, which 
is also considered as an independent risk factor 
for SCF in patients. It decreased even before the 
thickening of the carotid intima. Taken together, 
vascular endothelial dysfunction is thought to be 
closely associated with the pathogenesis of SCF. 
Flow-mediated vasodilation is widely accepted 
as a non-invasive method for vascular endothelial 
function evaluation and an indicator for early coro-
nary lesions [14]. NO and ET-1 are also considered 
biomarkers for vascular endothelial function. As the 
main diastolic vascular factor, CGRP interacts with 
its receptors on vascular endothelial cells, which 
Figure 2. Plasma nitric oxide (NO) (A), calcitonin gene-related peptide (CGRP) (B), endothelin-1 (ET-1) (C), and high sen-
sitivity C-reactive protein (hsCRP) (D) were measured in control and hyperbaric oxygen groups; *p < 0.01; **p < 0.001.
0
0
0
0
10
10
10
2
20
20
20
4
30
30
30
6
40 40
50 50
8
p = 0.785
p = 0.672
p = 0.842
p = 0.899
*
**
**
**
*
**
*
**
p = 0.798
p = 0.578
p = 0.723
p = 0.818
Control
Control
Control
Control
HBO
HBO
HBO
HBO
P
la
s
m
a
 N
O
 c
o
n
c
e
n
tr
a
ti
o
n
 [

M
]
P
la
s
m
a
 E
T
-1
 c
o
n
c
e
n
tr
a
ti
o
n
 [
p
g
/m
L
]
P
la
s
m
a
 C
G
R
P
 c
o
n
c
e
n
tr
a
ti
o
n
 [
p
g
/m
l]
P
la
s
m
a
 h
s
C
R
P
 c
o
n
c
e
n
tr
a
ti
o
n
 [
m
g
/L
]
A
C
B
D
Before treatment After treatment
www.cardiologyjournal.org 111
Yuan Li et al., HBO treatment improves vascular endothelial function in SCF patients
in turn enhances intracellular calcium levels via 
the cyclic adenosine monophosphate pathway [9]. 
This leads to enhanced activity of NO synthase, 
which further increases the vasodilatory effects of 
NO. Furthermore, hs-CRP, a maker of the inflam-
matory response involved in many types of acute 
and chronic physiological inflammation, is thought 
to be closely related to SCF onset [10, 11].
According to Bennett’s report [15], HBO treat-
ment can reduce myocardial ischemia and mortal-
ity rate of patients suffering from acute coronary 
syndrome. Another study from Khan et al. [16] 
showed that HBO treatment can increase myocar-
dial oxygen supply, and enhance the expression of 
vascular endothelial growth factors and the recov-
ery of cardiomyocytes, and can also significantly 
improve the efficacy of stem-cell transplantation-
treated myocardial infarct rats. Previous study 
also revealed that HBO treatment improved the 
symptoms of diabetic patients might be due to the 
effects of HBO on vascular functions. However, 
the potential mechanism is still unclear [17]. In 
addition, there are few reports on the effects of 
HBO treatment in improving vascular endothelial 
function of SCF patients.
In this study, in addition to regular, conven-
tional treatments, SCF patients were administrated 
with HBO therapy. As a result, patients who re-
ceived HBO treatment showed remarkably better 
FMD values and have significantly higher NO and 
CGRP levels, while lower ET-1 and hs-CRP levels 
compared to control SCF patients who received 
only conventional therapy. These data imply that 
HBO treatment could reduce patient vascular in-
flammatory response and, at the same time, reduce 
the expression of vasoconstrictor factors, such as 
ET-1, and also increase the expression of vasodi-
lators, including NO and CGRP, in reducing SCF 
symptoms. However, no significant change was 
observed in NMD measurement, which indicated 
the endothelium-independent diastolic function, 
further indicating that HBO therapy improves the 
symptom of SCF patients by enhancing the vascular 
endothelial functions.
In addition to its oxygen supply mechanism, 
HBO treatment can also exert influence in many 
other aspects: 1) Anti-oxidizing effects. Li et al. 
[18] found that HBO can improve the activity of 
catalase (CAT) and superoxide dismutase (SOD), 
while reducing the production of malondialdehyde 
(MDA) and large amounts of oxygen free radicals 
produced during ischemia-reperfusion; 2) Inhibit 
inflammation. According to Cheng et al. [19], HBO 
therapy can inhibit cyclooxygenase-2 (COX-2) 
and reduce the synthesis of prostaglandin (PG) 
and thromboxane A2 (TXA2); 3) HBO has been 
demonstrated to increase the expression of vari-
ous fibrinolytic factors in vascular endothelial cells, 
and reduce blood viscosity thus altering blood 
rheology [20]; 4) Promote the formation of collat-
eral circulation [21]; 5) Inhibit the development of 
atherosclerosis [22].
In a previous study, simvastatin was admin-
istered for 6 months to treat SCF patients [23]. 
Analysis using single photon emission computed 
tomography revealed a significant improvement in 
SCF, implying that simvastatin may exhibit statins-
like multi-efficacy benefits in blood vessels and 
cardiomyocytes in addition to its hypolipidemic 
effects. Caliskan et al. [24] also reported that ator-
vastatin improves the microvascular function of 
the coronary artery and increase coronary blood 
flow in SCF patients. However, in this study, SCF 
patients from the control group were administrated 
with statins, but no improvement was observed, 
this may be due to the relatively short-term ad-
ministration of the drugs. Further investigation is 
required to evaluate the efficacy of stains in chang-
ing endothelial function of SCF patients.
Limitation of the study
Noteworthy, HBO therapy still has many 
disadvantages which require further study. First, 
HBO treatment requires special equipment, which 
limits its daily practice for SCF patients. Second, 
long-term effects of HBO treatment, for example 
harmful oxidative stress on vascular function are 
still unclear and needs further study. It would be 
valuable to examine different conditions of HBO 
treatment and combination treatment to demon-
strate the most effective, while also minimizing 
harmful conditions for HBO therapy of SCF pa-
tients.
Conclusions
Taken together, HBO treatment can signifi-
cantly improve endothelial function of SCF pa-
tients, and may be therapeutically beneficial to 
SCF prognosis. In this study, a limited sample set 
was investigated and measurements were recorded 
over a relatively short-term period. Further in-
vestigation should be carried out with long-term 
prognostic follow-up of the patients.
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